Home › SEC Filings
SEC Filing Analysis
All Current Report (8-K)Annual Report (10-K)Quarterly Report (10-Q)Form 4 Insider TradesSC 13D Beneficial Ownership13F Institutional HoldingsPress ReleasesInsider Cluster ActivityInsider Buy Activity
Theme?
All themes Artificial IntelligenceSemiconductorsQuantum ComputingSpace & SatellitesRobotics & AutomationElectric VehiclesClean & Renewable EnergyBattery & Energy StorageNuclear & FusionCybersecurityCloud & SaaSFintech & PaymentsCrypto & BlockchainGenomics & Gene EditingBiotech & Drug DiscoveryE-commerce & PlatformsStreaming & Digital MediaGaming & EsportsDefense TechCannabis
| Ticker | Type | Sentiment | Impact | Summary | Date |
|---|---|---|---|---|---|
| STOK | 8-K | neutral | 2/10 | Stoke Therapeutics disclosed the resignation of board member Dr. Edward M. Kaye and the immediate appointment of Alexand | Sep 25, 2026 |
| TWST | CLUSTER | neutral | 3/10 | Three TWST insiders, including CEO Emily Leproust, sold a total of ~$273K in open-market sales over a 7-day window. The | Sep 25, 2026 |
| TBPH | SC 13D/A | neutral | 4/10 | Weiss Asset Management LP filed a Schedule 13D/A reporting that its stake in Theravance Biopharma was reduced to 0% as o | Sep 25, 2026 |
| BMRA | S-3 | bearish | 6/10 | Biomerica filed a $250M universal shelf registration statement (S-3) on September 24, 2026, registering common stock, pr | Sep 25, 2026 |
| KPTI | SC 13G/A | neutral | 3/10 | Acorn Bioventures L.P. and related entities filed an amended Schedule 13G disclosing an aggregate beneficial ownership o | Sep 25, 2026 |
| PHVS | CLUSTER | bearish | 6/10 | A significant insider selling cluster at Pharvaris N.V. (PHVS) totaling $7.46M in open-market sales over a one-week peri | Sep 25, 2026 |
| MBRX | 8-K | neutral | 4/10 | Moleculin Biotech announced new preclinical data at the AACR Pancreatic Cancer Conference showing that the antitumor act | Sep 25, 2026 |
| SLS | PRESS-RELEASE | neutral | 3/10 | SELLAS Life Sciences presented preclinical data at AACR showing its CDK9 inhibitor SLS009 induced substantially greater | Sep 25, 2026 |
| PHAR | 6-K | bullish | 6/10 | Pharming announced FDA acceptance and Priority Review of its sNDA for lower doses of Joenja (leniolisib) to treat childr | Sep 25, 2026 |
| KPTI | SC 13G/A | neutral | 3/10 | Acorn Bioventures, L.P. and related entities filed an amended Schedule 13G disclosing a combined beneficial ownership of | Sep 25, 2026 |
| PHAR | PRESS-RELEASE | bullish | 5/10 | Pharming announced FDA acceptance and Priority Review of its sNDA for lower doses of Joenja (leniolisib) in children age | Sep 25, 2026 |
| VTGN | 8-K | neutral | 4/10 | Vistagen filed an 8-K furnishing a new corporate presentation (Exhibit 99.1) that outlines its pipeline, clinical data, | Sep 25, 2026 |
| BAK | 6-K | bearish | 7/10 | Braskem disclosed a court decision in its extrajudicial reorganization proceeding, but has not yet been formally served | Sep 25, 2026 |
| CDT | 8-K | bearish | 5/10 | CDT Equity Inc. filed a certificate of amendment to effect a 1-for-25 reverse stock split of its common stock, effective | Sep 25, 2026 |
| CDT | PRESS-RELEASE | bearish | 6/10 | CDT Equity announced a 1-for-25 reverse stock split effective September 28, 2026, to regain compliance with Nasdaq's bid | Sep 25, 2026 |
| ADPT | PRESS-RELEASE | bullish | 6/10 | Adaptive Biotechnologies announced a new consensus definition of cure for multiple myeloma, established by IMS and IMWG, | Sep 25, 2026 |
| AQST | 8-K | neutral | 5/10 | Aquestive Therapeutics filed an 8-K with an investor presentation on September 23, 2026, highlighting the NDA resubmissi | Sep 25, 2026 |
| QUCY | 8-K | neutral | 3/10 | Quantum Cyber N.V. issued a press release and investor presentation announcing a sharpened strategic focus on three pill | Sep 25, 2026 |
| QUCY | PRESS-RELEASE | neutral | 3/10 | Quantum Cyber issued a press release reframing its strategic focus around three product pillars (one-way attack drones/i | Sep 25, 2026 |
| CCCC | 8-K | neutral | 4/10 | C4 Therapeutics presented new biomarker data at the 2026 IMS Annual Meeting showing cemsidomide drives T-cell activation | Sep 25, 2026 |
| NKTR | 8-K | bullish | 6/10 | Nektar Therapeutics won a $90 million jury verdict against Eli Lilly for breach of the implied covenant of good faith an | Sep 25, 2026 |
| LEGN | 6-K | bullish | 5/10 | Legend Biotech announced five-year follow-up data from CARTITUDE-2 Cohort A showing that 50% of RRMM patients remained p | Sep 25, 2026 |
| CCCC | PRESS-RELEASE | neutral | 4/10 | C4 Therapeutics presented biomarker data at IMS 2026 showing cemsidomide activates T cells and prevents exhaustion in RR | Sep 25, 2026 |
| LEGN | PRESS-RELEASE | bullish | 5/10 | Legend Biotech presented five-year follow-up data from CARTITUDE-2 Cohort A at IMS 2026, showing 50% of patients remaine | Sep 25, 2026 |
| ADXN | 6-K | neutral | 4/10 | Addex Therapeutics regained full global rights to its GABAB PAM portfolio from Indivior after Indivior rationalized R&D | Sep 25, 2026 |
| ATHE | 6-K | neutral | 2/10 | Alterity Therapeutics filed a routine 6-K announcing the date of its 2026 Annual General Meeting (November 20, 2026) and | Sep 25, 2026 |
| LABT | EFFECT | bullish | 6/10 | The SEC declared effective a registration statement (File No. 333-299027) for Lakewood-Amedex Biotherapeutics Inc. on Se | Sep 25, 2026 |
| ADRX | EFFECT | bullish | 8/10 | The SEC declared effective ADARx Pharmaceuticals' S-1 registration statement for its initial public offering of 21,875,0 | Sep 25, 2026 |
| SNTI | EFFECT | bearish | 7/10 | The SEC declared effective Senti Biosciences' shelf registration statement on Form S-3 (File No. 333-296917) on Septembe | Sep 25, 2026 |
| MLYS | CLUSTER | bearish | 5/10 | Three insiders at Mineralys Therapeutics sold a total of $3.30M in stock over a one-week window, led by director Brian T | Sep 24, 2026 |